Dietary exposure to an environmental toxin triggers neurofibrillary tangles and amyloid deposits in the brain

Paul Alan Cox, David A Davis, Deborah C Mash, James S Metcalf, Sandra Anne Banack, Paul Alan Cox, David A Davis, Deborah C Mash, James S Metcalf, Sandra Anne Banack

Abstract

Neurofibrillary tangles (NFT) and β-amyloid plaques are the neurological hallmarks of both Alzheimer's disease and an unusual paralytic illness suffered by Chamorro villagers on the Pacific island of Guam. Many Chamorros with the disease suffer dementia, and in some villages one-quarter of the adults perished from the disease. Like Alzheimer's, the causal factors of Guamanian amyotrophic lateral sclerosis/parkinsonism dementia complex (ALS/PDC) are poorly understood. In replicated experiments, we found that chronic dietary exposure to a cyanobacterial toxin present in the traditional Chamorro diet, β-N-methylamino-l-alanine (BMAA), triggers the formation of both NFT and β-amyloid deposits similar in structure and density to those found in brain tissues of Chamorros who died with ALS/PDC. Vervets (Chlorocebus sabaeus) fed for 140 days with BMAA-dosed fruit developed NFT and sparse β-amyloid deposits in the brain. Co-administration of the dietary amino acid l-serine with l-BMAA significantly reduced the density of NFT. These findings indicate that while chronic exposure to the environmental toxin BMAA can trigger neurodegeneration in vulnerable individuals, increasing the amount of l-serine in the diet can reduce the risk.

Keywords: Alzheimer's; BMAA; amyotrophic lateral sclerosis; cyanobacteria; l-serine; tau.

© 2016 The Authors.

Figures

Figure 1.
Figure 1.
Neuropathology of vervet brain tissue with chronic dietary BMAA exposures; a comparison of thioflavine-S and β-amyloid (1–42) immunoreactivity. (a) Thioflavine-S stained cells and neuropil threads in the motor cortex; scale bar, 150 µm. (b) Intraneuronal β-amyloid accumulation in neurons in motor cortex. (c) Vervet extracellular thioflavine-S deposits in the frontal cortex. (d) Localized β-amyloid immunostained neocortical deposits in vervet brains. (e) Thioflavine-S positive senile plaques and tangles in human AD temporal cortex. (f) β-amyloid senile plaques in human temporal cortex of AD patient (86-year-old male; 400× magnification). Human brain sections from AD patients were run as reference controls.
Figure 2.
Figure 2.
Microscopic pathology of chronic dietary l-BMAA exposures in vervets. Representative low-power images (5× magnification) of hyperphosphorylated tau (AT8) immunostained coronal hemisections from control (a,c) and l-BMAA-fed vervets (b,d). AT8 immunostaining is seen in the amygdala (Amy), entorhinal (EC), perirhinal (PrC), primary motor (M1) and temporal cortices of l-BMAA-fed vervets. Higher-power images show predominant tau AT8 staining in superficial cortical layers II and III with more robust staining over the entorhinal and perirhinal cortices (25× magnification) (d). Microscopic images (original magnification ×120) show NFT in vervets fed l-BMAA. Tangle-like tau aggregates are seen in the temporal gyrus (e,f). Dense intracellular tau immunolabelling (gi) and extracellular deposits (j,k) were seen in the parahippocampal gyrus. Abundant neuropil threads, tangles and dystrophic neuronal processes are observed in layers II and III of the perirhinal cortex (I, high-power images shown in l,m) and the paralaminar nucleus of the amygdala (n). Tau plaques were seen in l-BMAA-fed vervets ranging from large and diffuse (o) to small dense aggregates (p). ac, anterior commissure; Amy, amygdala; Bmc, basal nucleus of the amygdala, magnocellular region; Bpc, basal nucleus of the amygdala, parvicellular subdivision; Cd, caudate; cgs, cingulate gyrus sulcus; EC, entorhinal cortex; L, lateral nucleus of the amygdala; LF, lateral fissure; M1, primary motor cortex; PrC, perirhinal cortex; PL, paralaminar nucleus; Pu, putamen; STS, superior temporal sulcus.
Figure 3.
Figure 3.
Median counts for density of AT8 IHC positive staining inclusions plus NFT per brain area by treatment type. Each horizontal surface represents the median of an eight-vervet cohort statistically significant for dose using the Jonckheere–Terpstra trend test. (a) Brain regions in which AT8 IHC positive density counts from the 210 mg kg−1 d−1 BMAA treatment are greatest compared with other treatment types. (b) Brain regions in which AT8 IHC positive density counts from the 210 mg kg−1 d−1 BMAA plus 210 mg kg−1d−1 l-serine (high+SER) treatment is less than low-dose (low) BMAA (entorhinal cortex posterior) or in which low-dose NFT density is similar to controls (all other brain areas).
Figure 4.
Figure 4.
Theoretical pathways of development of ALS/PDC and AD neuropathology from chronic dietary BMAA exposure. (a) Tau proteins which bind microtubules become hyperphosphorylated, leading to dissociation of hyperphosphorylated tau fragments. These form paired helical filaments, leading to the formation of neurofibrillary tangles. (b) The APP is cleaved, producing β-amyloid (Aβ-42) fragments which are in an α-helix conformation. These change to a β-pleated sheet conformation, oligomerize, forming amyloid plaques.

References

    1. Cannon JR, Greenamyre JT. 2011. The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol. Sci. 124, 225–250. (10.1093/toxsci/kfr239)
    1. Langston JW, Ballard P, Tetrud JW, Irwin I. 1983. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis: Science 219, 979–980. (10.1126/science.6823561)
    1. Arnold A, Edgren DC, Palladino VS. 1953. Amyotrophic lateral sclerosis: fifty cases observed on Guam. J. Nerv. Ment. Dis. 117, 135–139. (10.1097/00005053195311720-00005)
    1. Hirano A, Malamud N, Kurland LT, Zimmerman HM. 1968. A review of the pathologic findings in amyotrophic lateral sclerosis. In Contemporary neurology symposium vol II: motor neuron diseases: research on amyotrophic lateral sclerosis and related disorders (eds Norris FH, Kurland LT), pp. 51–60. New York, NY: Grune and Stratton.
    1. Buée-Scherrer V, Buee L, Hof PR, Leveugle B, Gilles C, Loerzel AJ, Perl DP, Delacourte A. 1995. Neurofibrillary degeneration in amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam. Immunochemical characterization of tau proteins. Am. J. Pathol. 146, 924.
    1. Kurland LT, Radhakrishnan K, Williams DB, Waring SC. 1994. Amyotrophic lateral sclerosis-Parkinsonism-dementia complex on Guam: epidemiologic and etiological perspectives. In Motor neuron disease (ed. Williams AC.), pp. 109–130. London, UK: Chapman and Hall Medical.
    1. Garruto RM, Gajdusek DC, Chen KM. 1981. Amyotrophic lateral sclerosis and Parkinsonism-dementia among Filipino migrants to Guam. Ann. Neurol. 10, 341–350. (10.1002/ana.410100405)
    1. Garruto RM, Gajdusek DC, Chen KM. 1980. Amyotrophic lateral sclerosis among Chamorro migrants from Guam. Ann. Neurol. 8, 612–619. (10.1002/ana.410080612)
    1. Bell EA. 2009. The discovery of BMAA, and examples of biomagnification and protein incorporation involving other non-protein amino acids. Amyotroph. Lateral Scler. 10, 21–25. (10.3109/17482960903268700)
    1. Spencer PS, Nunn PB, Hugon J, Ludolph AC, Ross SM, Roy DN, Robertson RC. 1987. Guam amyotrophic lateral sclerosis-Parkinsonism-dementia linked to a plant excitant neurotoxin. Science 237, 517–522. (10.1126/science.3603037)
    1. Duncan MW. 1992. β-methylamino-L-alanine (BMAA) and amyotrophic lateral sclerosis-parkinsonism dementia of the Western Pacific. Ann. NY Acad. Sci. 648, 161–168. (10.1111/j.1749-6632.1992.tb24534.x)
    1. Cox PA, Banack SA, Murch SJ. 2003. Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam. Proc. Natl Acad. Sci. USA 100, 13 380–13 383. (10.1073/pnas.2235808100)
    1. Banack SA, Murch SJ, Cox PA. 2006. Neurotoxic flying foxes as dietary items for the Chamorro people, Marianas Islands. J. Ethnopharmacol. 106, 97–104. (10.1016/j.jep.2005.12.032)
    1. Cheng R, Banack SA. 2009. Previous studies underestimate BMAA concentrations in cycad flour. Amyotroph. Lateral Scler. 10, 41–43. (10.3109/17482960903273528)
    1. Murch SJ, Cox PA, Banack SA. 2004. A mechanism for slow release of biomagnified cyanobacterial neurotoxins and neurodegenerative disease in Guam. Proc. Natl Acad. Sci. USA 101, 12 228–12 231. (10.1073/pnas.0404926101)
    1. Jonasson S, Eriksson J, Berntzon L, Spáčil Z, Ilag L, Ronnevi L, Rasmussen U, Bergman B. 2010. Transfer of a cyanobacterial neurotoxin within a temperate aquatic ecosystem suggests pathways for human exposure. Proc. Natl Acad. Sci. USA 107, 9252–9257. (10.1073/pnas.0914417107)
    1. Brand LE, Pablo J, Compton A, Hammerschlag N, Mash DC. 2010. Cyanobacterial blooms and the occurrence of the neurotoxin, beta-N-methylamino-L-alanine (BMAA), in South Florida aquatic food webs. Harmful Algae 9, 620–635. (10.1016/j.hal.2010.05.002)
    1. Bradley WG, Borenstein AR, Nelson LM, Codd GA, Rosen BH, Stommel EW, Cox PA. 2013. Is exposure to cyanobacteria an environmental risk factor for amyotrophic lateral sclerosis and other neurodegenerative diseases? Amyotroph. Lateral Scler. Frontotemp. Degener. 14, 325–333. (10.3109/21678421.2012.750364)
    1. Torbick N, Hession S, Stommel E, Caller T. 2014. Mapping amyotrophic lateral sclerosis lake risk factors across northern New England. Int. J. Health Geogr. 13, 1–14. (10.1186/1476-072x-13-1)
    1. Sabel CE, Boyle PJ, Löytönen M, Gatrell AC, Jokelainen M, Flowerdew R, Maasilta P. 2003. Spatial clustering of amyotrophic lateral sclerosis in Finland at place of birth and place of death. Am. J. Epidemiol. 157, 898–905. (10.1093/aje/kwg090)
    1. Karlsson O, Berg AL, Hanrieder J, Arnerup G, Lindström AK, Brittebo EB. 2014. Intracellular fibril formation, calcification, and enrichment of chaperones, cytoskeletal, and intermediate filament proteins in the adult hippocampus CA1 following neonatal exposure to the nonprotein amino acid BMAA. Arch. Toxicol. 89, 423–436. (10.1007/s00204-014-1262-2)
    1. Karamyan VT, Speth RC. 2008. Animal models of BMAA neurotoxicity: a critical review. Life Sci. 82, 233–246. (10.1016/j.lfs.2007.11.020)
    1. Cox PA, et al. 2005. Diverse taxa of cyanobacteria produce β-N-methylamino-L-alanine, a neurotoxic amino acid. Proc. Natl Acad. Sci. USA 102, 5074–5078. (10.1073/pnas.0501526102)
    1. Downing S, Banack SA, Metcalf JS, Cox PA, Downing TG. 2011. Nitrogen starvation of cyanobacteria results in the production of β-N-methylamino-L-alanine. Toxicon 58, 187–194. (10.1016/j.toxicon.2011.05.017)
    1. Richer R, Banack SA, Metcalf JS, Cox PA. 2015. The persistence of cyanobacterial toxins in desert soils. J. Arid Environ. 112, 134–139. (10.1016/j.jaridenv.2014.01.023)
    1. Cox PA, Richer R, Metcalf JS, Banack SA, Codd GA, Bradley WG. 2009. Cyanobacteria and BMAA exposure from desert dust: a possible link to sporadic ALS among Gulf War veterans. Amyotroph. Lateral Scler. 10, 109–117. (10.3109/17482960903286066)
    1. Metcalf JS, Banack SA, Lindsay J, Morrison LF, Cox PA, Codd GA. 2008. Co-occurrence of β-N-methylamino-L-alanine, a neurotoxic amino acid with other cyanobacterial toxins in British waterbodies, 1990–2004. Environ. Microbiol. 10, 702–708. (10.1111/j.1462-2920.2007.01492.x)
    1. Liu X, Rush T, Zapata J, Lobner D. 2009. β-N-methylamino-L-alanine induces oxidative stress and glutamate release through action on system Xc−. Exp. Neurol. 217, 429–433. (10.1016/j.expneurol.2009.04.002)
    1. Rao SD, Banack SA, Cox PA, Weiss JH. 2006. BMAA selectively injures motor neurons via AMPA/kainate receptor activation. Exp. Neurol. 201, 244–252. (10.1016/j.expneurol.2006.04.017)
    1. Chiu AS, Gehringer MM, Braidy N, Guillemin GJ, Welch JH, Neilan BA. 2013. Gliotoxicity of the cyanotoxin, β-methyl-amino-L-alanine (BMAA). Sci. Rep. 3, 1482 (10.1038/srep01482)
    1. Yin HZ, Yu S, Hsu C-I, Liu J, Acab A, Wu R, Tao A, Chiang BJ, Weiss JH. 2014. Intrathecal infusion of BMAA induces selective motor neuron damage and astrogliosis in the ventral horn of the spinal cord. Exp. Neurol. 261, 1–9. (10.1016/j.expneurol.2014.06.003)
    1. Rush T, Liu X, Lobner D. 2012. Synergistic toxicity of the environmental neurotoxins methylmercury and β-N-methylamino-L-alanine. Neuroreport 23, 216–219. (10.1097/wnr.0b013e32834fe6d6)
    1. Xie X, Basile M, Mash DC. 2013. Cerebral uptake and protein incorporation of cyanobacterial toxin β-N-methylamino-L-alanine. Neuroreport 24, 779–784. (10.1097/wnr.0b013e328363fd89)
    1. Dunlop RA, Cox PA, Banack SA, Rodgers KJ. 2013. The non-protein amino acid BMAA is misincorporated into human proteins in place of L-serine causing protein misfolding and aggregation. PLoS ONE 8, e75376 (10.1371/journal.pone.0075376)
    1. Lee JW, et al. 2006. Editing-defective tRNA synthetase causes protein misfolding and neurodegeneration. Nature 443, 50–55. (10.1038/nature05096)
    1. Arif M, Kazim SF, Grundke-Iqbal I, Garruto RM, Iqbal K. 2014. Tau pathology involves protein phosphatase 2A in Parkinsonism-dementia of Guam. Proc. Natl Acad. Sci. USA 111, 1144–1149. (10.1073/pnas.1322614111)
    1. Pablo J, Banack SA, Cox PA, Johnson TE, Papapetropoulos S, Bradley WG, Buck A, Mash DC. 2009. Cyanobacterial neurotoxin BMAA in ALS and Alzheimer's disease. Acta Neurol. Scand. 120, 216–225. (10.1111/j.1600-0404.2008.01150.x)
    1. Koch R. 1880. Investigations into the etiology of traumatic infective diseases (trans. WW Cheyne) London, UK: The New Sydenham Society.
    1. LaFerla FM, Oddo S. 2005. Alzheimer's disease: Aβ, tau and synaptic dysfunction. Trends Mol. Med. 11, 170–176. (10.1016/j.molmed.2005.02.009)
    1. Heuer E, Rosen RF, Cintron A, Walker LC. 2012. Nonhuman primate models of Alzheimer-like cerebral proteopathy. Curr. Pharm. Des. 18, 1159–1169. (10.2174/138161212799315885)
    1. Lemere CA, et al. 2004. Alzheimer's disease Aβ vaccine reduces central nervous system Aβ levels in a non-human primate, the Caribbean vervet. Am. J. Pathol. 165, 283–297. (10.1016/s0002-9440(10)63296-8)
    1. Dunn WD, Gearing M, Park Y, Zhang L, Hanfelt J, Glass JD, Gutman DA. In press. Applicability of digital analysis and imaging technology in neuropathology assessment. Neuropathology. (10.1111/neup.12273)
    1. Glover WB, Baker TC, Murch SJ, Brown PN. 2015. Determination of β-N-methylamino-L-alanine, N-(2-aminoethyl)glycine, and 2,4-diaminobutyric acid in food products containing cyanobacteria by ultra-performance liquid chromatography and tandem mass spectrometry: single-laboratory validation. J. AOAC Int. 98, 1559–1567. (10.5740/jaoacint.15-084)
    1. Banack SA, Downing TG, Spácil Z, Purdie E, Metcalf JS, Downing S, Esterhuizen M, Codd GA, Cox PA. 2010. Distinguishing the cyanobacterial neurotoxin β-N-methylamino-L-alanine (BMAA) from its structural isomer 2,4-diaminobutyric acid (2,4-DAB). Toxicon 56, 868–879. (10.1016/j.toxicon.2010.06.006)
    1. Banack SA, Metcalf JS, Jiang L, Craighead D, Ilag LL, Cox PA. 2012. Cyanobacteria produce N-(2-aminoethyl)glycine, a backbone for peptide nucleic acids which may have been the first genetic molecules for life on earth. PLoS ONE 7, e49043 (10.1371/journal.pone.0049043)
    1. Murch SJ, Cox PA, Banack SA, Steele JC, Sacks OW. 2004. Occurrence of β-methylamino-L-alanine (BMAA) in ALS/PDC patients from Guam. Acta Neurol. Scand. 110, 267–269. (10.1111/j.1600-0404.2004.00320.x)
    1. Hof PR, Perl DP, Loerzel AJ, Steele JC, Morrison JH. 1994. Amyotrophic lateral sclerosis and parkinsonism-dementia from Guam: differences in neurofibrillary tangle distribution and density in the hippocampal formation and neocortex. Brain Res. 650, 107–116. (10.1016/0006-8993(94)90212-7)
    1. Oyanagi K, Makifuchi T, Ohtoh T, Chen KM, van der Schaaf T, Gajdusek DC, Chase TN, Ikuta F. 1994. Amyotrophic lateral sclerosis of Guam: the nature of the neuropathological findings. Acta Neuropathol. 88, 405–412. (10.1007/bf00389491)
    1. Braak H, Braak E. 1995. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging 16, 271–278. (10.1016/0197-4580(95)00021-6)
    1. Schmidt ML, Lee VY, Saido T, Perl D, Schuck T, Iwatsubo T, Trojanowski JQ. 1998. Amyloid plaques in Guam amyotrophic lateral sclerosis/parkinsonism-dementia complex contain species of Aβ similar to those found in the amyloid plaques of Alzheimer's disease and pathological aging. Acta Neuropathol. 95, 117–122. (10.1007/s004010050774)

Source: PubMed

3
Iratkozz fel